top of page
News, Events and Updates
Search
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
2 hours ago
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Apr 5
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 31
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
Feb 12
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
Jan 15
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
Jan 13
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Dec 23, 2024
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
Dec 23, 2024
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Dec 9, 2024
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
Nov 26, 2024
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
Nov 25, 2024
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Oct 31, 2024
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Aug 6, 2024
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
May 9, 2024
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP)
Dec 19, 2023
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Nov 24, 2023
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease
Nov 20, 2023
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of
Oct 25, 2023
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease
Sep 14, 2023
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Aug 2, 2023
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
